ESC Heart Failure (Aug 2023)

Mortality rate after coronary revascularization in heart failure patients with coronary artery disease

  • Vanessa Nader,
  • Anthony Matta,
  • Ryeonshi Kang,
  • Antoine Deney,
  • Rania Azar,
  • Charlotte Rouzaud‐Laborde,
  • Oxana Kunduzova,
  • Romain Itier,
  • Pauline Fournier,
  • Michel Galinier,
  • Didier Carrié,
  • Jerome Roncalli

DOI
https://doi.org/10.1002/ehf2.14445
Journal volume & issue
Vol. 10, no. 4
pp. 2656 – 2663

Abstract

Read online

Abstract Aims Coronary artery disease (CAD) is a common cause of heart failure (HF). It remains unclear who, when and why to direct towards coronary revascularization. The outcomes of coronary revascularization in HF patients are still a matter of debate nowadays. This study aims to evaluate the effect of revascularization strategy on all‐cause of death in the context of ischaemic HF. Methods and results An observational cohort was conducted on 692 consecutive patients who underwent coronary angiography at the University Hospital of Toulouse between January 2018 and December 2021 for either a recent diagnosis of HF or a decompensated chronic HF, and in whom coronary angiograms showed at least 50% obstructive coronary lesion. The study population was divided into two groups according to the performance or not of a coronary revascularization procedure. The living status (alive or dead) of each of the study's participants was observed by April 2022. Seventy‐three per cent of the study population underwent coronary revascularization either by percutaneous coronary intervention (66.6%) or coronary artery bypass grafting (6.2%). Baseline characteristics including age, sex and cardiovascular risk factors did not differ between the invasive and conservative groups, respectively. Death occurred in 162 study participants resulting in an all‐cause mortality rate of 23.5%; 26.7% of observed deaths have occurred in the conservative group versus 22.2% in the invasive group (P = 0.208). No difference in survival outcomes has been observed over a mean follow‐up period of 2.5 years (P = 0.140) even after stratification by HF categories (P = 0.132) or revascularization modalities (P = 0.366). Conclusions Findings from the present study showed comparable all‐cause mortality rates between groups. Coronary revascularization does not modify short‐term survival outcomes in HF patients compared with optimal medical therapy alone outside the setting of acute coronary syndrome.

Keywords